sur Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Protagonist Therapeutics to Present at J.P. Morgan Healthcare Conference
Protagonist Therapeutics, Inc., headquartered in Newark, CA, is set to participate in the 43rd Annual J.P. Morgan Healthcare Conference from January 12-16, 2025, in San Francisco. Dinesh V. Patel, Ph.D., the President and CEO, will offer a company overview on January 14 at 8:15 AM PT. The presentation can be accessed via webcast and will remain available on the company's Investor Relations webpage for one year.
Protagonist Therapeutics specializes in developing novel peptides. The company is advancing its leading candidates: Icotrokinra, an oral peptide targeting the IL-23 receptor for disorders like plaque psoriasis, and Rusfertide, targeting polycythemia vera. Both are in the late stages of clinical trials, with significant collaborations supporting their progress.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Protagonist Therapeutics, Inc.